Follow RSS for latest reports on this topicTecfidera (Dimethyl Fumarate) - Market Research and Reports

TECFIDERA® (dimethyl fumarate) is an oral therapy approved in the United States for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS), which is the most common form of the disease. TECFIDERA has been proven to significantly reduce important measures of disease activity, including relapses and development of brain lesions, as well as to slow disability progression over time, while demonstrating a favorable safety and tolerability profile.

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Related Reports:

We found over 40 reports that matched your search.

Next 40 Matches >

Refine your search, and find more matches, using the form above.

Published:
2018-02-07

Published by: GBI Research

Prices Starting From:
$4995

Additional Searches

You may also like to search separately for: Tecfidera (Dimethyl Fumarate)

We Stock...

{STICKYFOOTERMOBILE}